KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EBT (2016 - 2025)

AbbVie (ABBV) has disclosed EBT for 14 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 217.58% to $2.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 billion, a 77.53% increase, with the full-year FY2025 number at $6.6 billion, up 77.53% from a year prior.
  • EBT was $2.7 billion for Q4 2025 at AbbVie, up from $714.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $4.9 billion in Q1 2022 to a low of -$2.3 billion in Q4 2024.
  • A 5-year average of $2.2 billion and a median of $2.0 billion in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: surged 383.41% in 2021, then crashed 287.21% in 2024.
  • AbbVie's EBT stood at $4.3 billion in 2021, then plummeted by 30.58% to $3.0 billion in 2022, then plummeted by 59.12% to $1.2 billion in 2023, then plummeted by 287.21% to -$2.3 billion in 2024, then skyrocketed by 217.58% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBT are $2.7 billion (Q4 2025), $714.0 million (Q3 2025), and $1.6 billion (Q2 2025).